Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non–Squamous Non–Small Cell Lung Cancer
Open Access
- 4 February 2022
- journal article
- research article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 23 (3) , 214-225
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group studyGynecologic Oncology, 2015
- Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancerCancer Medicine, 2014
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2014
- 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced diseaseAnnals of Oncology, 2014
- Artd1/Parp1 regulates reprogramming by transcriptional regulation of Fgf4 via Sox2 ADP-ribosylationStem Cells, 2013
- Prediction of Lung Cancer Histological Types by RT-qPCR Gene Expression in FFPE SpecimensThe Journal of Molecular Diagnostics, 2013
- SRY (sex determining region Y)-box2 (Sox2)/poly ADP-ribose polymerase 1 (Parp1) complexes regulate pluripotencyProceedings of the National Academy of Sciences, 2012
- Use of Archived Specimens in Evaluation of Prognostic and Predictive BiomarkersJNCI: Journal of the National Cancer Institute, 2009
- ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor ModelsClinical Cancer Research, 2007
- The PARP superfamilyBioEssays, 2004